FDA approval could shape liver disease treatment landscape
A novel liver therapy authorised under US Food and Drug Administration (FDA) Accelerated Approval, is a potential game-changer in the NASH treatment space.
List view / Grid view
A novel liver therapy authorised under US Food and Drug Administration (FDA) Accelerated Approval, is a potential game-changer in the NASH treatment space.
Insilico Medicine’s novel AI-generated small molecule inhibitor drug represents a new milestone in pharmaceutical drug development.
Aramchol reduced liver fibrosis progression in 15 out of 16 patients and did not worsen non-alcoholic steatohepatitis in almost half of patients.
A study has shown that crystallising drugs removes localised immune reaction, allowing long-term release of drugs from medical devices.